246 related articles for article (PubMed ID: 18083377)
21. Chemotherapy for melanoma: the resultant of conflicting vectors.
Mitchell MS
J Clin Oncol; 2004 Jun; 22(11):2043-5. PubMed ID: 15123732
[No Abstract] [Full Text] [Related]
22. Chemotherapy for metastatic melanoma: time for a change?
Gogas HJ; Kirkwood JM; Sondak VK
Cancer; 2007 Feb; 109(3):455-64. PubMed ID: 17200963
[TBL] [Abstract][Full Text] [Related]
23. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
24. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
[TBL] [Abstract][Full Text] [Related]
25. [Disseminated melanoma treatment].
Neidhardt-Bérard EM; Négrier S
Rev Prat; 2004 Jun; 54(11):1210-4. PubMed ID: 15496028
[TBL] [Abstract][Full Text] [Related]
26. Systemic treatment of malignant melanoma.
Mota A; Deisseroth A
Clin Plast Surg; 2000 Jul; 27(3):463-74, x. PubMed ID: 10941566
[TBL] [Abstract][Full Text] [Related]
27. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
28. The systemic treatment of advanced cutaneous melanoma.
Logan TF
Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
[No Abstract] [Full Text] [Related]
29. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
30. Randomized trials in melanoma: an update.
Eggermont AM
Surg Oncol Clin N Am; 2006 Apr; 15(2):439-51. PubMed ID: 16632225
[TBL] [Abstract][Full Text] [Related]
31. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
Lorigan P; Eisen T; Hauschild A
Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for recurrent and metastatic cervical cancer.
Tao X; Hu W; Ramirez PT; Kavanagh JJ
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
[TBL] [Abstract][Full Text] [Related]
33. New approaches in metastatic melanoma: biological and molecular targeted therapies.
Lejeune FJ; Rimoldi D; Speiser D
Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
[TBL] [Abstract][Full Text] [Related]
34. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
35. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
36. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
37. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
Tarhini AA; Millward M; Mainwaring P; Kefford R; Logan T; Pavlick A; Kathman SJ; Laubscher KH; Dar MM; Kirkwood JM
Cancer; 2009 Feb; 115(4):859-68. PubMed ID: 19140204
[TBL] [Abstract][Full Text] [Related]
38. Tumor angiogenesis in melanoma.
Marneros AG
Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
[TBL] [Abstract][Full Text] [Related]
39. New therapeutical strategies in the treatment of metastatic disease.
Julia F; Thomas L; Dalle S
Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
[TBL] [Abstract][Full Text] [Related]
40. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D
Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
